Revvity, Inc. (BIT:1RVTY)
Italy · Delayed Price · Currency is EUR 74.32
+0.44 (0.60%)
At close: Sep 19, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2015 - 2020 |
Discovery & Analytical Solutions Product Revenue (Pre-Q3 2022) | - | Log In | Log In | Log In | Log In | Upgrade |
Discovery & Analytical Solutions Product Revenue (Pre-Q3 2022) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Discovery & Analytical Solutions Service Revenue (Pre-Q3 2022) | - | Log In | Log In | Log In | Log In | Upgrade |
Discovery & Analytical Solutions Service Revenue (Pre-Q3 2022) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Diagnostics Product Revenue (Pre-Q3 2022) | - | Log In | Log In | Log In | Log In | Upgrade |
Diagnostics Product Revenue (Pre-Q3 2022) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Diagnostics Service Revenue (Pre-Q3 2022) | - | Log In | Log In | Log In | Log In | Upgrade |
Diagnostics Service Revenue (Pre-Q3 2022) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Total Diagnostics Revenue (Pre-Q3 2022) | 1.50B | Log In | Log In | Log In | Log In | Upgrade |
Total Diagnostics Revenue (Pre-Q3 2022) Growth | 4.25% | Log In | Log In | Log In | Log In | Upgrade |
Total Discovery & Analytical Solutions Revenue (Post-Q2 2022) | 1.25B | Log In | Log In | Log In | Log In | Upgrade |
Total Discovery & Analytical Solutions Revenue (Post-Q2 2022) Growth | 2.36% | Log In | Log In | Log In | Log In | Upgrade |
Total Product | 2.34B | Log In | Log In | Log In | Log In | Upgrade |
Total Product Growth | -0.08% | Log In | Log In | Log In | Log In | Upgrade |
Total Service | 416.82M | Log In | Log In | Log In | Log In | Upgrade |
Total Service Growth | 24.78% | Log In | Log In | Log In | Log In | Upgrade |
Life Sciences Revenue (Pre-Q3 2022) | - | Log In | Log In | Log In | Log In | Upgrade |
Life Sciences Revenue (Pre-Q3 2022) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Applied Markets Revenue (Pre-Q3 2022) | - | Log In | Log In | Log In | Log In | Upgrade |
Applied Markets Revenue (Pre-Q3 2022) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2015 - 2020 |
Other | 36.59M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 122.84% | Log In | Log In | Log In | Log In | Upgrade |
Discovery & Analytical Solutions Operating Income (Pre-Q3 2022) | - | Log In | Log In | Log In | Log In | Upgrade |
Discovery & Analytical Solutions Operating Income (Pre-Q3 2022) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 36.59M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 122.84% | Log In | Log In | Log In | Log In | Upgrade |
Diagnostics Operating Income (Pre-Q3 2022) | 373.19M | Log In | Log In | Log In | Log In | Upgrade |
Diagnostics Operating Income (Pre-Q3 2022) Growth | 10.02% | Log In | Log In | Log In | Log In | Upgrade |
Discovery & Analytical Solutions Operating Income (Post-Q2 2022) | 448.02M | Log In | Log In | Log In | Log In | Upgrade |
Discovery & Analytical Solutions Operating Income (Post-Q2 2022) Growth | 0.98% | Log In | Log In | Log In | Log In | Upgrade |